- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Fasenra approved in the US for self-administration
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Update on US regulatory review of PT010 in COPD
AnnouncementREG - AstraZeneca PLC - AstraZeneca divests rights for Losec to Cheplaphar
AnnouncementREG - AstraZeneca PLC - Lynparza more than doubled the time without
AnnouncementREG - AstraZeneca PLC - Lynparza improved the time women lived without
AnnouncementREG - AstraZeneca PLC - Tagrisso is the only 1st-line treatment for EGFR-
AnnouncementREG - AstraZeneca PLC - Qtrilmet recommended for approval in EU by CHMP
AnnouncementREG - AstraZeneca PLC - AstraZeneca amends collaboration with Ironwood
AnnouncementREG - AstraZeneca PLC - Imfinzi is first immunotherapy to show both
AnnouncementREG - AstraZeneca PLC - Tagrisso approved in China as a 1st-line treatment
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Detailed results from Phase III DAPA-HF trial
AnnouncementREG - AstraZeneca PLC - Brilinta reduced the risk of cardiovascular events
AnnouncementREG - AstraZeneca PLC - Anifrolumab Phase III trial meets primary endpoint
AnnouncementREG - AstraZeneca PLC - Breztri Aerosphere Phase III ETHOS trial met
Announcement